1. TAVR valves now FDA approved for low-risk patients
   The FDA's decision will expand TAVR access to younger, healthier patients.
2. FDA approves baroreflex activation for advanced HF
   A phase 4 trial will investigate impact on hospitalizations and mortality.
3. Top line results: Dapagliflozin meets primary endpiont in DAPA-HF
   AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor.
4. Cardiovascular cost of smoking may last up to 25 years
   Past smokers face an elevated cardiovascular risk for up to 25 years.

You can contact the MDedge Cardiocast by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.